Daniel Low-Beer
Overview
Explore the profile of Daniel Low-Beer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1053
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stelzle D, Rangaraj A, Jarvis J, Razakasoa N, Perrin G, Low-Beer D, et al.
Lancet Glob Health
. 2025 Feb;
13(3):e437-e446.
PMID: 40021302
Background: Advanced HIV disease (AHD) is a critical stage in the progression of HIV infection and is associated with heightened susceptibility to opportunistic infections, malignancies, and other life-threatening complications. Estimates...
2.
Artenie A, Trickey A, Looker K, Stone J, Lim A, Fraser H, et al.
Lancet Gastroenterol Hepatol
. 2025 Feb;
10(4):315-331.
PMID: 39993400
Background: Measuring progress towards the WHO 2030 target for hepatitis C virus (HCV) elimination among people who inject drugs (PWID)-an incidence of two or fewer infections per 100 person-years-has been...
3.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
4.
Moorhouse L, Gregson S, Imai-Eaton J, Mayini J, Dadirai T, Magoge-Mandizvidza P, et al.
medRxiv
. 2024 Sep;
PMID: 39314941
Background: Differentiating risk for HIV infection is important for providing focussed prevention options to individuals. We conducted a longitudinal study to validate a risk-differentiation tool for predicting HIV or HSV-2...
5.
Artenie A, Stone J, Fraser H, Stewart D, Arum C, Lim A, et al.
Lancet Gastroenterol Hepatol
. 2023 Mar;
8(6):533-552.
PMID: 36996853
Background: Measuring the incidence of HIV and hepatitis C virus (HCV) infection among people who inject drugs (PWID) is key to track progress towards elimination. We aimed to summarise global...
6.
Cui F, Blach S, Mingiedi C, Gonzalez M, Alaama A, Mozalevskis A, et al.
Lancet Gastroenterol Hepatol
. 2023 Feb;
8(4):332-342.
PMID: 36764320
Background: The 69th World Health Assembly endorsed the global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health threat by 2030. Achieving and measuring the...
7.
Renaud F, Mofenson L, Bakker C, Dolk H, Leroy V, Namiba A, et al.
J Int AIDS Soc
. 2022 Jul;
25 Suppl 2:e25922.
PMID: 35851994
Introduction: As new antiretrovirals (ARVs), including long-acting ARVs for treatment and prevention, are approved and introduced, surveillance during pregnancy must become the safety net for evaluating birth outcomes, especially those...
8.
Taylor M, Wi T, Gerbase A, Thwin S, Gottlieb S, Babovic M, et al.
PLoS One
. 2022 May;
17(5):e0263550.
PMID: 35507535
Background: In 2016, WHO launched the Global Health Sector Strategy on STIs, 2016-2021 (GHSS) to provide guidance and benchmarks for country achievement by 2020 and four global targets for achievement...
9.
Barbaric J, Kuchukhidze G, Seguy N, Vovc E, Babovic M, Wi T, et al.
Euro Surveill
. 2022 Feb;
27(8).
PMID: 35209970
BackgroundEpidemics of sexually transmitted infections (STI) are a major public health challenge in the World Health Organization (WHO) European Region.AimWe aimed to provide an overview of case reporting and other...
10.
Le L, Blach S, Rewari B, Chan P, Fuqiang C, Ishikawa N, et al.
Liver Int
. 2021 Dec;
42(9):1930-1934.
PMID: 34894047
In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021. We examine the...